SCHEMBL24251114

SCHEMBL24251114

CCN1CCC(c2ccc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)c(C(F)(F)F)c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 7/20 0.65
PDGFRA P16234 5/20 0.65
KDR P35968 4/20 0.65
ABL1 P00519 16/20 0.61
BCR P11274 8/20 0.60
LYN P07948 6/20 0.60
PDGFRB P09619 4/20 0.58
LCK P06239 2/20 0.54
FYN P06241 2/20 0.54
RET P07949 2/20 0.54
BRAF P15056 2/20 0.54
NQO2 P16083 2/20 0.54
EPHA2 P29317 2/20 0.54
EPHB2 P29323 2/20 0.54
CSK P41240 2/20 0.54
ABL2 P42684 2/20 0.54
FRK P42685 2/20 0.54
EPHB3 P54753 2/20 0.54
EPHA5 P54756 2/20 0.54
EPHB4 P54760 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29551218 1.00 KIT (0.65) KITPDGFRAKDRABL1BCR
SCHEMBL24251111 0.95 KIT (0.63) KITPDGFRAKDRABL1BCR
SCHEMBL29551205 0.95 KIT (0.63) KITPDGFRAKDRABL1BCR
SCHEMBL29551834 0.93 KIT (0.62) KITPDGFRAKDRABL1BCR
SCHEMBL24251067 0.93 KIT (0.62) KITPDGFRAKDRABL1BCR
SCHEMBL24251103 0.92 ABL1 (0.66) KITPDGFRAKDRABL1BCR
SCHEMBL29551423 0.92 ABL1 (0.66) KITPDGFRAKDRABL1BCR
SCHEMBL24251156 0.92 ABL1 (0.56) KITPDGFRAKDRABL1BCR
SCHEMBL24250916 0.89 KIT (0.61) KITPDGFRAKDRABL1BCR
SCHEMBL29551427 0.89 KIT (0.61) KITPDGFRAKDRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114127065-A Compounds for the treatment of neurodegenerative diseases and cancer 鸿仪有限责任公司 2022-03-01 CN claimed
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers HONGYI & ASS LLC (US) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers SNCA, NGF, SLC18A2 KIT 2333/4885PDGFRA 145/4885KDR 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.